New UHPLC Method for Cannabidiol Determination in Hard Capsules

1. Kogan NM, Melamed E, Wasserman E et al. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. J Bone Miner Res. 2015;30:1905-1913.10.1002/jbmr.251325801536Search in Google Scholar

2. Rong C, Lee Y, Carmona NE et al. Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacol Res. 2017;121:213-218.10.1016/j.phrs.2017.05.00528501518Search in Google Scholar

3. National Center for Biotechnology Information. PubChem Compound Database; CID=644019, https://pubchem.ncbi.nlm.nih.gov/compound/644019 (accessed December 9, 2018).Search in Google Scholar

4. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-150.10.1016/j.pharmthera.2017.02.04128232276Search in Google Scholar

5. Lucas CJ, Galettis P, Schneider J et al. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477-2482.10.1111/bcp.13710617769830001569Search in Google Scholar

6. Jalali SAM, Johnson WE. The Development of Cannabidiol as a Psychiatric Therapeutic: a Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms. International Neuropsychiatric Disease Journal. 2013;1:113-147.10.9734/INDJ/2013/6192Search in Google Scholar

7. Paudel KS, Hammell DC, Agu RU et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm, 2010;36: 1088–1097.10.3109/0363904100365729520545522Search in Google Scholar

8. Peres F, Lima AC, Hallak JEK et al. Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. Front Pharmacol. 2018;11:482-484.10.3389/fphar.2018.00482595819029867488Search in Google Scholar

9. Fernández-Ruiz J, Sagredo O, Pazos MR et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol. 2013;75:323-333.10.1111/j.1365-2125.2012.04341.x357924822625422Search in Google Scholar

10. Rock EM, Bolognini D, Limebeer CL et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol. 2012;165:2620-2634.10.1111/j.1476-5381.2011.01621.x342324121827451Search in Google Scholar

11. Oláh A, Tóth BI, Borbíró I. et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014;124:3713-3724.10.1172/JCI64628415123125061872Search in Google Scholar

12. Couch DG, Tasker C, Theophilidou et al. Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin Sci. 2017;131:2611-2626.10.1042/CS2017128828954820Search in Google Scholar

13. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377-1385.10.1016/j.bmc.2015.01.05925703248Search in Google Scholar

14. Avula A, Chandsana H, Setlow B et al. Simultaneous quantification of cannabinoids tetrahydrocannabinol,cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant. J pharm Biomed Anal. 2018;160:119-125.10.1016/j.jpba.2018.07.004639765130077950Search in Google Scholar

15. Zgair A, Wong JCM, Sabri A et al. Development of a simple and sensitive HPLC–UV method for thesimultaneous determination of cannabidiol and_9-tetrahydrocannabinol in rat plasma. J Pharm Biomed Anal. 2015;114:145-151.10.1016/j.jpba.2015.05.01926048666Search in Google Scholar